- Home
- DBI vs GNLX Comparison
DBI vs GNLX Comparison
Compare DBI & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBI
- GNLX
- Stock Information
- Founded
- DBI 1991
- GNLX 2001
- Country
- DBI United States
- GNLX United States
- Employees
- DBI N/A
- GNLX N/A
- Industry
- DBI Clothing/Shoe/Accessory Stores
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- DBI Consumer Discretionary
- GNLX Health Care
- Exchange
- DBI Nasdaq
- GNLX Nasdaq
- Market Cap
- DBI 222.4M
- GNLX 184.4M
- IPO Year
- DBI 1991
- GNLX 2023
- Fundamental
- Price
- DBI $3.65
- GNLX $2.70
- Analyst Decision
- DBI Hold
- GNLX Strong Buy
- Analyst Count
- DBI 2
- GNLX 4
- Target Price
- DBI $4.75
- GNLX $18.25
- AVG Volume (30 Days)
- DBI 1.7M
- GNLX 167.0K
- Earning Date
- DBI 03-20-2025
- GNLX 03-28-2025
- Dividend Yield
- DBI 5.63%
- GNLX N/A
- EPS Growth
- DBI N/A
- GNLX N/A
- EPS
- DBI N/A
- GNLX N/A
- Revenue
- DBI $3,009,262,000.00
- GNLX $8,000.00
- Revenue This Year
- DBI $3.51
- GNLX N/A
- Revenue Next Year
- DBI $2.60
- GNLX N/A
- P/E Ratio
- DBI N/A
- GNLX N/A
- Revenue Growth
- DBI N/A
- GNLX N/A
- 52 Week Low
- DBI $3.20
- GNLX $1.60
- 52 Week High
- DBI $11.06
- GNLX $6.50
- Technical
- Relative Strength Index (RSI)
- DBI 41.31
- GNLX 32.11
- Support Level
- DBI $3.71
- GNLX $3.03
- Resistance Level
- DBI $4.42
- GNLX $3.35
- Average True Range (ATR)
- DBI 0.32
- GNLX 0.36
- MACD
- DBI 0.04
- GNLX -0.11
- Stochastic Oscillator
- DBI 36.48
- GNLX 0.00
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment, and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.